David Brown

2.5k total citations · 1 hit paper
34 papers, 2.0k citations indexed

About

David Brown is a scholar working on Organic Chemistry, Molecular Biology and Pharmacology. According to data from OpenAlex, David Brown has authored 34 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Organic Chemistry, 11 papers in Molecular Biology and 10 papers in Pharmacology. Recurrent topics in David Brown's work include Antibiotic Resistance in Bacteria (6 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Inflammatory mediators and NSAID effects (5 papers). David Brown is often cited by papers focused on Antibiotic Resistance in Bacteria (6 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Inflammatory mediators and NSAID effects (5 papers). David Brown collaborates with scholars based in United States, United Kingdom and Australia. David Brown's co-authors include John J. Talley, Karen Seibert, Matthew J. Graneto, Carol M. Koboldt, Jeffery S. Carter, Arnold Louie, George L. Drusano, Jaime L. Masferrer, Ben S. Zweifel and Roland S. Rogers and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

David Brown

34 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2

2000 569 citations John J. Talley, David Brown et al. Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Brown United States	25	803	786	443	279	278	34	2.0k
Joanne J. Bronson United States	23	745 0.9×	300 0.4×	780 1.8×	366 1.3×	357 1.3×	74	1.8k
John P. O’Donnell United States	20	493 0.6×	588 0.7×	682 1.5×	121 0.4×	306 1.1×	51	2.4k
Éric Marsault Canada	27	800 1.0×	704 0.9×	1.3k 2.9×	156 0.6×	102 0.4×	81	2.7k
Silvana Grasso Italy	33	1.7k 2.1×	406 0.5×	1.2k 2.7×	326 1.2×	416 1.5×	136	3.3k
Khalid Islam Italy	28	339 0.4×	233 0.3×	1.3k 2.8×	317 1.1×	172 0.6×	72	2.4k
Kathryn M. Nelson United States	18	249 0.3×	371 0.5×	848 1.9×	176 0.6×	206 0.7×	37	2.3k
Steven Swaney United States	12	502 0.6×	318 0.4×	534 1.2×	643 2.3×	176 0.6×	14	1.6k
Kerim Babaoglu United States	19	454 0.6×	186 0.2×	1.0k 2.3×	412 1.5×	203 0.7×	20	1.8k
Walter E. DeWolf United States	26	620 0.8×	147 0.2×	984 2.2×	119 0.4×	77 0.3×	50	1.9k
Aiming Sun United States	29	401 0.5×	149 0.2×	947 2.1×	156 0.6×	455 1.6×	42	2.1k

Countries citing papers authored by David Brown

Since Specialization

Citations

This map shows the geographic impact of David Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Brown more than expected).

Fields of papers citing papers by David Brown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Brown. The network helps show where David Brown may publish in the future.

Co-authorship network of co-authors of David Brown

This figure shows the co-authorship network connecting the top 25 collaborators of David Brown. A scholar is included among the top collaborators of David Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Brown. David Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hu, Yanhong, Xudong Zhou, Shanjuan Wang, et al.. (2021). Diarrhoea Management using Over-the-counter Nutraceuticals in Daily practice (DIAMOND): a feasibility RCT on alternative therapy to reduce antibiotic use. Pilot and Feasibility Studies. 7(1). 126–126. 2 indexed citations

Drusano, George L., David Brown, Michael S. Maynard, et al.. (2018). Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation. International Journal of Antimicrobial Agents. 53(3). 275–283. 17 indexed citations

Brown, David, Michael Mulligan, & Richard L. Uhl. (2013). Volar Ligament Repair for Radiocarpal Fracture-dislocation. Orthopedics. 36(6). 463–468. 11 indexed citations

Winters, Jeffrey L., et al.. (2011). Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. BMC Health Services Research. 11(1). 101–101. 68 indexed citations

Louie, Arnold, et al.. (2010). The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression. Antimicrobial Agents and Chemotherapy. 54(6). 2646–2654. 59 indexed citations

Wang, Jane L., James R. Kiefer, Ravi G. Kurumbail, et al.. (2010). The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: The first clinical candidate. Bioorganic & Medicinal Chemistry Letters. 20(23). 7155–7158. 43 indexed citations

Drusano, George L., et al.. (2010). The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill ofMycobacterium tuberculosisas Determined in a Hollow-Fiber Infection Model. mBio. 1(3). 62 indexed citations

Wang, Jane L., Karl Aston, David C. Limburg, et al.. (2010). The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates. Bioorganic & Medicinal Chemistry Letters. 20(23). 7164–7168. 33 indexed citations

Louie, Arnold, David Brown, Weiguo Liu, et al.. (2007). In Vitro Infection Model Characterizing the Effect of Efflux Pump Inhibition on Prevention of Resistance to Levofloxacin and Ciprofloxacin in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy. 51(11). 3988–4000. 19 indexed citations

10.

Toy, Patrick C., et al.. (2007). Reconstruction of Noncontained Proximal Tibial Defects with Divergent Screws and Cement. Clinical Orthopaedics and Related Research. 459. 167–173. 4 indexed citations

11.

Gumbo, Tawanda, Arnold Louie, Weiguo Liu, et al.. (2006). Isoniazid’s Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion ofMycobacterium tuberculosisin the Log Phase of Growth. The Journal of Infectious Diseases. 195(2). 194–201. 78 indexed citations

12.

Freskos, John N., Yvette M. Fobian, Timothy E. Benson, et al.. (2006). Design of potent inhibitors of human β-secretase. Part 1. Bioorganic & Medicinal Chemistry Letters. 17(1). 73–77. 31 indexed citations

13.

Freskos, John N., Yvette M. Fobian, Timothy E. Benson, et al.. (2006). Design of potent inhibitors of human β-secretase. Part 2. Bioorganic & Medicinal Chemistry Letters. 17(1). 78–81. 30 indexed citations

14.

Talley, John J., David Brown, Jeffery S. Carter, et al.. (2000). 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2. Journal of Medicinal Chemistry. 43(5). 775–777. 569 indexed citations breakdown →

15.

Talley, John J., Stephen R. Bertenshaw, David Brown, et al.. (1999). 4,5-Diaryloxazole inhibitors of cyclooxygenase-2 (COX-2). Medicinal Research Reviews. 19(3). 199–208. 32 indexed citations

16.

McWherter, Charles A., Warren J. Rocque, Mark E. Zupec, et al.. (1997). Scanning Alanine Mutagenesis and De-peptidization of a Candida albicans Myristoyl-CoA:ProteinN-Myristoyltransferase Octapeptide Substrate Reveals Three Elements Critical for Molecular Recognition. Journal of Biological Chemistry. 272(18). 11874–11880. 29 indexed citations

17.

Sikorski, James A., Balekudru Devadas, Mark E. Zupec, et al.. (1997). Selective peptidic and peptidomimetic inhibitors of Candida albicans myristoylCoA: Protein N-myristoyltransferase: A new approach to antifungal therapy. Biopolymers. 43(1). 43–71. 46 indexed citations

18.

Devadas, Balekudru, Mark E. Zupec, Sandra K. Freeman, et al.. (1995). Design and Syntheses of Potent and Selective Dipeptide Inhibitors of Candida albicans Myristoyl-CoA:Protein N-Myristoyltransferase. Journal of Medicinal Chemistry. 38(11). 1837–1840. 53 indexed citations

19.

Williams, David R., et al.. (1985). Total synthesis of (.+-.)-ilicicolin H. The Journal of Organic Chemistry. 50(15). 2807–2809. 40 indexed citations

20.

Weinstein, Arthur, et al.. (1972). Metabolism of the third component of complement (C3) in patients with rheumatoid arthritis. Arthritis & Rheumatism. 15(1). 49–56. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact